ALK and lung adenocarcinoma: Furthermore, in the context of H3122 lung adenocarcinoma, research findings suggested that the combination of ALK inhibition with a PI3K inhibitor (ZSTK474) or anticoccidial agent (salinomycin) reversed stem-like cell characteristics and impeded the development of acquired resistance.